RxDoctor Payments Data

Jane Grimberg

Family · Dayton, OHNPI 1356657084

Payments from drug & device makers

$1,541in general payments, 2019–2025

Across 18 payments — averaging $85.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$261
  • Bayer$246
  • E.r. Squibb & Sons, L.L.C.$238
  • Johnson & Johnson$229
  • Boston Scientific$172
  • Edwards Lifesciences$119
  • plus $275 from 6 others

What the payments were for

  • Food & beverage$1,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,541 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$50,587
Medicare patients
406
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban706$816,601
XareltoRivaroxaban179$198,939
Repatha SureclickEvolocumab163$191,580
EntrestoSacubitril/Valsartan125$144,530
JardianceEmpagliflozin76$81,761
FarxigaDapagliflozin Propanediol50$57,696
BrilintaTicagrelor17$16,712
Repatha SyringeEvolocumab11$14,212
Ranolazine ErRanolazine129$10,746
Metoprolol Succinate893$10,048
Rosuvastatin Calcium566$5,806
Ezetimibe257$5,725
Atorvastatin Calcium756$5,675
VascepaIcosapent Ethyl14$4,848
Prasugrel Hcl17$4,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$816,601706 claims
Johnson & JohnsonXarelto$229$198,939179 claims
Boehringer IngelheimJardiance$46$81,76176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →